Spyre Therapeutics, Inc.
Burrows Scott L (Chief Financial Officer) sold 7,500 shares of Spyre Therapeutics, Inc. (SYRE) at an average of $95.57 ($95.21–$97.10, $0.72M total) across 3 trades on 2026-08-03 under a Rule 10b5-1 trading plan.
Turtle Cameron (Chief Executive Officer) sold 15,000 shares of Spyre Therapeutics, Inc. (SYRE) at an average of $95.51 ($93.97–$97.46, $1.43M total) across 5 trades on 2026-08-03 under a Rule 10b5-1 trading plan.
Spyre Therapeutics, Inc. (SYRE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 spyre-20260630xexx991.htm EX-99.1 Document Exhibit 99.1 Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Announced positive topline induction data for SPY001 and SPY002 from Part A of the Phase 2 SKYLINE trial (“SKYLINE”), d
Over the past 7 days, alphai's AI scored 1 news story mentioning SYRE (Spyre Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent SYRE coverage spans insider activity, earnings and financial news.
In the last 30 days, SYRE insiders filed 8 SEC Form 4 transactions — no purchases and 8 sales ($2.1M). The most active reporter was Turtle Cameron, Chief Executive Officer, with 5 filings. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
This is a routine insider-sale disclosure with no stated operational or financial catalyst, so it is more of a sentiment signal than a fundamental change.
This is a routine insider-sale disclosure with limited direct signal value, but it can affect near-term sentiment if traders treat it as a read-through on confidence.
The filing strengthens near-term clinical momentum (positive induction efficacy and safety) and extends visibility into multiple 2026 proof-of-concept catalysts, while reiterating a long cash runway.
This is an insider sale disclosure; it may modestly affect sentiment but does not change fundamentals by itself.
Routine 10b5-1 insider sale reduces near-term signaling value; it’s unlikely to change fundamentals by itself.
alphai scores every news story that mentions SYRE with an AI model for sentiment and relevance, and aggregates insider trades from Spyre Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Burrows Scott L (Chief Financial Officer) sold 7,500 shares of Spyre Therapeutics, Inc. (SYRE) at an average of $95.57 ($95.21–$97.10, $0.72M total) across 3 trades on 2026-08-03 under a Rule 10b5-1 trading plan.
1 min readTurtle Cameron (Chief Executive Officer) sold 15,000 shares of Spyre Therapeutics, Inc. (SYRE) at an average of $95.51 ($93.97–$97.46, $1.43M total) across 5 trades on 2026-08-03 under a Rule 10b5-1 trading plan.
2 min readSpyre Therapeutics, Inc. (SYRE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 spyre-20260630xexx991.htm EX-99.1 Document Exhibit 99.1 Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Announced positive topline induction data for SPY001 and SPY002 from Part A of the Phase 2 SKYLINE trial (“SKYLINE”), d
6 min readBurrows Scott L (Chief Financial Officer) sold 7,500 shares of Spyre Therapeutics, Inc. (SYRE) at an average of $87.74 ($87.55–$88.37, $0.66M total) across 2 trades on 2026-07-01 under a Rule 10b5-1 trading plan.
1 min readSloan Sheldon (Chief Medical Officer) sold 8,334 shares of Spyre Therapeutics, Inc. (SYRE) at an average of $87.70 ($87.52–$88.34, $0.73M total) across 2 trades on 2026-07-01 under a Rule 10b5-1 trading plan.
2 min readTurtle Cameron (Chief Executive Officer) sold 15,000 shares of Spyre Therapeutics, Inc. (SYRE) at an average of $87.69 ($87.44–$88.91, $1.32M total) across 3 trades on 2026-07-01 under a Rule 10b5-1 trading plan.
2 min readBurrows Scott L (Chief Financial Officer) sold 15,000 shares of Spyre Therapeutics, Inc. (SYRE) at an average of $87.13 ($87.12–$87.14, $1.31M total) across 2 trades on 2026-06-25.
1 min readSpyre Therapeutics (NASDAQ:SYRE) shares fell 13.7% in premarket trading after SEC Form 4 filings showed major insider-related sales. Fairmount Healthcare Fund II L.P., affiliated with Spyre directors, sold 4,684,781 common shares on June 23 for about $399.7 million, leaving zero common shares. Spyre director Michael Thomas Henderson sold 20,000 shares for about $2 million under a Rule 10b5-1 plan.
4 min readFairmount Funds Management LLC sold 4,684,781 indirectly-held shares of Spyre Therapeutics, Inc. (SYRE) at $85.31 ($399.66M total) on 2026-06-23.
2 min readHENDERSON MICHAEL THOMAS sold 20,000 shares of Spyre Therapeutics, Inc. (SYRE) at $100.00 ($2.00M total) on 2026-06-22 under a Rule 10b5-1 trading plan.
1 min read